We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+4.31%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.43B
AUM Growth
+$292M
(+26%)
Cap. Flow
+$65.8M
Cap. Flow
% of AUM
4.59%
Top 10 Holdings %
Top 10 Hldgs %
64.89%
Holding
82
New
14
Increased
33
Reduced
12
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Community Health Systems
CYH
|
+$37.3M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$35M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$19.9M |
| 4 |
AMED
Amedisys
AMED
|
+$19.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$14.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$77.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$27.1M |
| 3 |
Envista
NVST
|
+$21.6M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$17.9M |
| 5 |
Haleon
HLN
|
+$15.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.06% |
| 2 | Miscellaneous | 22.43% |
| 3 | Financials | 0.95% |
| 4 | Communication Services | 0.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Evolus
EOLS
$587M
| $1.87M | 0.13% |
221,551
-492,223
| -69% | -$4.45M |
|
52
Agilent Technologies
A
$43.4B
| $1.81M | 0.13% |
13,110
+1,232
| +10% | +$180K |
|
53
Gossamer Bio
GOSS
$83.2M
| $1.7M | 0.12% |
1,352,065
+1,197,853
| +777% | +$2.29M |
|
54
Revvity
RVTY
$14.4B
| $1.64M | 0.11% |
12,335
+1,157
| +10% | +$152K |
|
|
PRTK
55
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $1.62M | 0.11% |
+638,474
| New | +$1.26M |
|
56
argenx
ARGX
$64B
| $1.43M | 0.1% |
3,836
+360
| +10% | +$133K |
|
|
AFMD
57
DELISTED
Affimed
AFMD
| $1.4M | 0.1% |
188,378
+155,356
| +470% | +$1.55M |
|
|
JBIO
58
Jade Biosciences
JBIO
$1.33B
| $1.01M | 0.07% |
1,435
-1,172
| -45% | -$972K |
|
59
Repligen
RGEN
$9.95B
| $952K | 0.07% |
5,656
-51,348
| -90% | -$9.16M |
|
|
WHWK
60
Whitehawk Therapeutics
WHWK
$263M
| $738K | 0.05% |
101,918
| – | – |
|
61
NewAmsterdam Pharma
NAMS
$3.1B
| $608K | 0.04% |
+45,856
| New | +$579K |
|
62
AC Immune
ACIU
$263M
| $292K | 0.02% |
124,589
| – | – |
|
|
APLS
63
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-154,796
| Closed | -$8M |
|
64
Bolt Biotherapeutics
BOLT
$7.35M
| – | – |
-1,559
| Closed | -$40.5K |
|
65
Cabaletta Bio
CABA
$529M
| – | – |
-282,874
| Closed | -$2.62M |
|
|
66
CALL
Community Health Systems
CYH
$413M
| – | – |
-312,900
| Closed | -$1.35M |
|
67
Eledon Pharmaceuticals
ELDN
$260M
| – | – |
-67,743
| Closed | -$154K |
|
68
Fate Therapeutics
FATE
$291M
| – | – |
-43,562
| Closed | -$440K |
|
|
CBIO
69
Crescent Biopharma
CBIO
$659M
| – | – |
-1,006
| Closed | -$305K |
|
70
CALL
GSK
GSK
$102B
| – | – |
-2,093,700
| Closed | -$73.6M |
|
|
71
Haleon
HLN
$44.5B
| – | – |
-1,881,470
| Closed | -$15.1M |
|
72
Incyte
INCY
$25.2B
| – | – |
-63,996
| Closed | -$5.14M |
|
73
CALL
Merck
MRK
$366B
| – | – |
-48,700
| Closed | -$5.4M |
|
|
74
Envista
NVST
$4.36B
| – | – |
-642,405
| Closed | -$21.6M |
|
75
Pliant Therapeutics
PLRX
$68.7M
| – | – |
-137,423
| Closed | -$2.66M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q1 2023 Portfolio in Review
As of Q1 2023, Eversept Partners held 82 positions worth $1.43B, up 26% from $1.14B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Eversept Partners deployed $65.8M of net new capital in Q1 2023, opening 14 new positions and adding to 33 existing holdings. Its largest new stake was Amedisys: 224,263 shares worth $16.5M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $27.1M trimmed.
- Eversept Partners's largest Q1 2023 buy was Amedisys: 224,263 shares worth $16.5M.
- Eversept Partners added most to Community Health Systems in Q1 2023, an estimated $37.3M increase.
- Eversept Partners's biggest Q1 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $27.1M.
- Eversept Partners fully exited Sanofi in Q1 2023, selling an estimated $77.7M.
- Eversept Partners's ten largest holdings make up 65% of its $1.43B portfolio in Q1 2023.
- Eversept Partners opened 14 new positions and closed 20 in Q1 2023.
- Eversept Partners's portfolio value rose 26% quarter-over-quarter to $1.43B.
Based on Eversept Partners's 13F filing for Q1 2023, filed 15 May 2023.